WithdrawnNot Applicable

Mohs and Immunofluorescence for Malignant Melanoma In Situ

Stopped: PI is leaving the University of Miami

United States0Started 2015-06

Plain-language summary

The purpose of this study is to determine if immunofluorescence (IF) can effectively identify features of malignant melanoma in situ, on sun-damaged skin, in the setting of Mohs Micrographic Surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female of any race and at least 18 years of age
✓. Patient with biopsied proven Lentigo maligna (LM) in situ
✓. Patient meets criteria for Mohs Micrographic Surgery (MMS)
✓. The cancer is large
✓. The edges of the cancer (clinical margins) cannot be clearly defined
✓. Prior treatment has failed, i.e. recurrent tumor
✓. The cancer is located in a cosmetically sensitive or functionally critical area of the body (such as eyelids, nose, ears, lips, fingers, toes, and genitals)
✓. The histologic pattern of the cancer is aggressive

Exclusion criteria

✕. Patients under the age of 18
✕. Patient does not meet criteria for MMS or has LM located in areas that are not accessible with MMS
✕. Patient with previously diagnosed invasive LM
✕. Patients unable to comply with follow-up
✕. Adults unable to consent
✕. Pregnant women
✕

What they're measuring

IF MART-1 versus Standard H&E and IHC MART-1

Timeframe: End of Mohs Surgery, approximately up to 24 hours

Trial details

NCT IDNCT02306512

SponsorUniversity of Miami

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-11

View on ClinicalTrials.gov More Lentigo Maligna trials